Novel Antifungal Olorofim Clears Valley Fever in 75% of Hard-to-Treat Cases
A mid-stage trial finds olorofim effective in three-quarters of patients with disseminated Valley fever who had no other treatment options.
Summary
Valley fever, a fungal lung infection affecting hundreds of thousands of Americans yearly, can spread to the brain and spine in its most severe form — a condition requiring lifelong treatment with few cures. A new phase IIb clinical trial tested olorofim, an investigational antifungal drug, in 41 patients with this hard-to-treat disseminated form of the disease. After 42 days, nearly 76% showed a meaningful clinical response. Results were strongest in patients without brain or spinal involvement, and weakest in those with central nervous system infections and implanted devices. Published in Annals of Internal Medicine, the findings suggest olorofim may offer a viable rescue therapy for patients who have exhausted all standard antifungal options.
Detailed Summary
Valley fever — caused by inhaling spores of the Coccidioides fungus found in arid soils — infects an estimated 206,000 to 360,000 Americans annually. In about 1% of cases, the infection disseminates beyond the lungs, spreading to bones, skin, and the central nervous system. This disseminated coccidioidomycosis (DCM) is notoriously difficult to treat, requiring lifelong antifungal therapy and rarely resolving completely.
A phase IIb open-label trial published in Annals of Internal Medicine evaluated the investigational antifungal olorofim in 41 patients with DCM who had failed or could not tolerate standard treatments. After 42 days, 75.6% showed a complete or partial clinical response; at 84 days, 73.2% maintained that response. These figures compare favorably with existing azole therapies — particularly notable given that all participants had refractory or progressive disease.
Response rates varied significantly by disease location. Patients without central nervous system (CNS) infection fared best, achieving an 80% success rate. Among those with CNS infection but no implanted devices, success dropped to 64.7%. Patients with CNS infections and implanted CNS devices had the lowest response rate at 41.7%, highlighting the compounding challenge of hardware-associated infections.
Olorofim belongs to a new class of antifungals called orotomides, which work by inhibiting a fungal enzyme essential for pyrimidine synthesis — a mechanism distinct from existing drugs. This novel mode of action may explain its activity against strains resistant to current therapies.
Key caveats apply: this was a small, open-label trial without a control arm, and participants had been living with DCM for an average of nearly three years before enrollment. Larger, controlled studies are needed before olorofim can become a standard option. Still, for patients with no remaining treatment alternatives, these results represent a meaningful clinical advance.
Key Findings
- 75.6% of DCM patients unresponsive to standard antifungals showed clinical improvement on olorofim after 42 days.
- Patients without CNS involvement had an 80% response rate versus 41.7% in those with CNS infections and implanted devices.
- Olorofim uses a novel mechanism — blocking fungal pyrimidine synthesis — distinct from all existing antifungal drug classes.
- All 41 trial participants had failed prior antifungal therapy, making the response rate especially significant.
- Valley fever disseminates in roughly 1% of cases, requiring lifelong treatment with current drugs and rarely resolving fully.
Methodology
This is a news report summarizing a peer-reviewed phase IIb open-label clinical trial published in Annals of Internal Medicine. The study enrolled 41 patients, making it a small but specialized cohort of refractory cases. As a subanalysis of a larger trial without a randomized control arm, findings should be interpreted with caution pending larger confirmatory studies.
Study Limitations
The trial was small (41 patients), open-label, and lacked a randomized control arm, limiting definitive efficacy conclusions. All participants had advanced, refractory disease, so results may not generalize to earlier-stage or less severe DCM cases. The article content was truncated, and the full definition of partial clinical response was not available for review.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: